Cite
HARVARD Citation
Saiag, P. et al. (n.d.). 1260PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma. Annals of oncology. p. . [Online].